FDA Clearance Tracker · P140003-S110
Impella 2.5, Impella CP and CP with SmartAssist
Last checked: Nov 20, 2026Latest source record: Apr 27, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Apr 27, 2023
Approved
Time to decision
30 days
Received Mar 28, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P140003-S110
- Device name
- Impella 2.5, Impella CP and CP with SmartAssist
- Applicant
- Abiomed, Inc.
- Applicant location
- Danvers, MA
- Received
- Mar 28, 2023
- Decided
- Apr 27, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P140003
Device type
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the Impella Real-World Surveillance of patients using Sodium Bicarbonate. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval orders for P140003/S088 and P170011/S035.
Source documents
Other decisions for Abiomed, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252766 · Decided Oct 8, 2025 · 40 days after receipt
Device type: Introducer, Catheter (DYB) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.